First Time Loading...

Chengdu Olymvax Biopharmaceuticals Inc
SSE:688319

Watchlist Manager
Chengdu Olymvax Biopharmaceuticals Inc Logo
Chengdu Olymvax Biopharmaceuticals Inc
SSE:688319
Watchlist
Price: 9.52 CNY -0.1%
Updated: May 29, 2024

Profitability Summary

47/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Chengdu Olymvax Biopharmaceuticals Inc

Revenue
548m CNY
Cost of Revenue
-41.4m CNY
Gross Profit
506.6m CNY
Operating Expenses
-475.7m CNY
Operating Income
30.9m CNY
Other Expenses
-6.8m CNY
Net Income
24.1m CNY

Margins Comparison
Chengdu Olymvax Biopharmaceuticals Inc Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
CN
Chengdu Olymvax Biopharmaceuticals Inc
SSE:688319
3.9B CNY
92%
6%
4%
US
Abbvie Inc
NYSE:ABBV
274.3B USD
66%
29%
11%
US
Amgen Inc
NASDAQ:AMGN
161B USD
66%
24%
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.4B USD
87%
41%
39%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
107.2B USD
86%
30%
29%
AU
CSL Ltd
ASX:CSL
135.6B AUD
52%
26%
17%
US
Gilead Sciences Inc
NASDAQ:GILD
79.7B USD
76%
32%
2%
US
Moderna Inc
NASDAQ:MRNA
58.7B USD
22%
-100%
-116%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
75%
-33%
-33%
US
Biogen Inc
NASDAQ:BIIB
31.8B USD
75%
22%
12%
KR
Celltrion Inc
KRX:068270
36.9T KRW
47%
21%
17%
Country CN
Market Cap 3.9B CNY
Gross Margin
92%
Operating Margin
6%
Net Margin
4%
Country US
Market Cap 274.3B USD
Gross Margin
66%
Operating Margin
29%
Net Margin
11%
Country US
Market Cap 161B USD
Gross Margin
66%
Operating Margin
24%
Net Margin
13%
Country US
Market Cap 115.4B USD
Gross Margin
87%
Operating Margin
41%
Net Margin
39%
Country US
Market Cap 107.2B USD
Gross Margin
86%
Operating Margin
30%
Net Margin
29%
Country AU
Market Cap 135.6B AUD
Gross Margin
52%
Operating Margin
26%
Net Margin
17%
Country US
Market Cap 79.7B USD
Gross Margin
76%
Operating Margin
32%
Net Margin
2%
Country US
Market Cap 58.7B USD
Gross Margin
22%
Operating Margin
-100%
Net Margin
-116%
Country US
Market Cap 43.1B USD
Gross Margin
75%
Operating Margin
-33%
Net Margin
-33%
Country US
Market Cap 31.8B USD
Gross Margin
75%
Operating Margin
22%
Net Margin
12%
Country KR
Market Cap 36.9T KRW
Gross Margin
47%
Operating Margin
21%
Net Margin
17%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Chengdu Olymvax Biopharmaceuticals Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CN
Chengdu Olymvax Biopharmaceuticals Inc
SSE:688319
3.9B CNY
3%
2%
3%
2%
US
Abbvie Inc
NYSE:ABBV
274.3B USD
56%
4%
15%
13%
US
Amgen Inc
NASDAQ:AMGN
161B USD
73%
4%
10%
9%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.4B USD
24%
19%
23%
33%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
107.2B USD
15%
12%
14%
17%
AU
CSL Ltd
ASX:CSL
135.6B AUD
15%
7%
11%
9%
US
Gilead Sciences Inc
NASDAQ:GILD
79.7B USD
3%
1%
18%
7%
US
Moderna Inc
NASDAQ:MRNA
58.7B USD
-38%
-29%
-29%
-56%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-28%
-21%
-27%
-39%
US
Biogen Inc
NASDAQ:BIIB
31.8B USD
8%
5%
9%
8%
KR
Celltrion Inc
KRX:068270
36.9T KRW
4%
3%
4%
3%
Country CN
Market Cap 3.9B CNY
ROE
3%
ROA
2%
ROCE
3%
ROIC
2%
Country US
Market Cap 274.3B USD
ROE
56%
ROA
4%
ROCE
15%
ROIC
13%
Country US
Market Cap 161B USD
ROE
73%
ROA
4%
ROCE
10%
ROIC
9%
Country US
Market Cap 115.4B USD
ROE
24%
ROA
19%
ROCE
23%
ROIC
33%
Country US
Market Cap 107.2B USD
ROE
15%
ROA
12%
ROCE
14%
ROIC
17%
Country AU
Market Cap 135.6B AUD
ROE
15%
ROA
7%
ROCE
11%
ROIC
9%
Country US
Market Cap 79.7B USD
ROE
3%
ROA
1%
ROCE
18%
ROIC
7%
Country US
Market Cap 58.7B USD
ROE
-38%
ROA
-29%
ROCE
-29%
ROIC
-56%
Country US
Market Cap 43.1B USD
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country US
Market Cap 31.8B USD
ROE
8%
ROA
5%
ROCE
9%
ROIC
8%
Country KR
Market Cap 36.9T KRW
ROE
4%
ROA
3%
ROCE
4%
ROIC
3%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More